Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HMMR/CD168 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HMMR/CD168 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View HMMR Products |
| Gene Delivery | HMMR/CD168 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View HMMR Products |
| Benchmark Ab | Anti-HMMR/CD168 (Sequence of Clinical Clone) Recombinant positive control. |
View HMMR Products |
| Validator | HMMR/CD168 siRNA Set For knockdown verification. |
View HMMR Products |
| Related Target A | CD44 Primary co-receptor for Hyaluronan (HA); synergizes with HMMR to drive oncogenic signaling. |
View CD44 Products |
| Related Target B | HAS2 (Hyaluronan Synthase 2) Synthesizes the extracellular HA ligand; critical for microenvironment modeling. |
View HAS2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native conformation on cell membrane for CAR-T/mAb binding | Lentivirus Premade Particles for stable cell line generation to preserve native conformation and membrane presentation |
| Hyaluronan (HA) binding competition assays | HEK293-expressed recombinant HMMR protein with native glycosylation and verified high-purity sequence |
| Lack of clinical benchmark controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration |
| False positive results in phenotypic screening | Sequence-verified siRNA knockdown sets included for target specificity validation |
Live HMMR/CD168 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HMMR/CD168 therapeutics is intensifying, with major players shifting focus from traditional peptide vaccines to advanced cellular therapies (CAR-T/TCR-T) and targeted antibody-drug conjugates (ADCs). As first-generation peptide therapies reach mature clinical phases in hematological malignancies, the next wave of R&D is targeting solid tumor microenvironments where HMMR-mediated motility drives metastasis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CAR-T / TCR-T | Academic Medical Centers, Biotech Startups | Acute Myeloid Leukemia (AML), Multiple Myeloma, Glioma | Cell-based binding & activation assays (Requires Lentivirus for stable HMMR-expressing target cells) |
| Peptide Vaccine | University of Ulm, Phase II/III Consortia | Myelodysplastic Syndromes (MDS), AML | MHC peptide binding stability assays & flow cytometry validation |
| Monoclonal Antibodies / ADCs | Preclinical Stage Biopharma | Breast Cancer, Glioblastoma, Pancreatic Cancer | Internalization assays & HA-blocking assays (Requires high-purity, glycosylated ECD-Fc fusion protein) |